Shu-Jen CHEN


Dr. Shu-Jen Chen received her Ph.D. degree in Biochemistry from Virginia Commonwealth University, did her Postdoctoral training at Baylor College of Medicine, and was a Research Assistant Professor at SUNY Buffalo.  She joined National Health Research Institute (NHRI) as an Assistant Investigator and established the high throughput screening program for the institute. As one of the founding scientists, Dr. Chen joined TaiGen Biotechnology in 2001 to lead the in vitro pharmacology group. In 2006, she moved to Chang Gung University as an Associate Professor of the Department of Biomedical Sciences. As a co-founder of ACT Genomics, Dr. Chen has served as the Chief Scientific Officer since 2014. Dr. Chen specializes in automated drug screening system, genomics and transcriptomics technologies, omics data analysis and biological database integration. She is also familiar with cancer biology, system integration and database design. She currently leads the sequencing group and the bioinformatics group at ACT Genomics to implement cancer genome sequencing for research and clinical applications.



Cancer is a group of genetic diseases. Each tumor evolves from its genetic alteration, which also governs its response to treatment. Thus, to better diagnose, treat, and monitor the disease, it is important to understand the genomic alteration of an individual tumor. Recent advance in next-generation sequencing (NGS) technology has enabled the profiling of hundreds to thousands of genes in disease tissue and liquid biopsy at different disease stage. Each sample source has its advantages and limitation. Similarly, using DNA or RNA as the starting material may offer different insights into the genetic alteration. Sequencing scope and depth will also affect the sensitivity and usability of the testing results. Thus, selecting an appropriate genetic test becomes an important consideration for oncologists and patients. This talk will review the genetic test currently used in oncology field and discuss the technology as well as the clinical aspect when choosing the test.

Share This Speaker
Speaker Details
  • Affiliations of the Speaker
    Taiwan Precision Medicine Society
Laboratory aspects of Precision Medicine in Oncology

7th November 2020,17:00pm

Events of the Speaker
You might also love these events.
November 7, 2020
The highlights for the 7th HKIOS include application of artificial intelligence in radiotherapy planning and biomarkers discovery, ultra-high dose rate (FLASH) radiotherapy and alternating electric fields (tumour treating fields or TTF). Many oncologists are not familiar with these brand-new modalities, which are being slowly incorporated into our clinical practice. Due to Covid-19 pandemic, we shall conduct our symposium virtually. We thank our local and overseas speakers for their stern support and contribution again.
October 26, 2019
The 6th Hong Kong International Oncology Symposium (6th HKIOS) was conducted in Sheraton Hong Kong Hotel & Towers on 26th and 27th October. The event was joined by renowned speakers with a higher international representation, reflecting our initiatives in fostering international medical collaborations. Some emerging topics such as artificial intelligence, immunotherapy and radiotherapy were discussed in the symposium.